Meeting in Chicago last week, the American Medical Association House of Delegates passed a resolution to “petition the Food and Drug Administration and the Federal Trade Commission to ban the advertising of prescription drugs to the general public.”
The practice of major pharmaceutical companies using direct-to-consumer advertising of prescription drugs, or DTCA, has become increasingly controversial in recent years. Many medical professionals believe that this advertising has led to an increase in unnecessary prescriptions, which has led to a further escalation of health care costs. Others, including the drug companies, counter that DTCA advertising has helped make consumers aware of health care options and helped empower patients to find the best medical care possible.
Both sides in this debate have valid points. However, considering the state of health care in the United States where high cost has become the central issue, the relationship between the dramatic rise in prescription drug usage and drug advertising deserves an additional look from the FDA and FTC.
Informing consumers is legitimate, and fostering communication in the patient-physician relationship is good, but slick advertising for prescription pharmaceuticals is unnecessary.
An outright ban on DTCA advertising is not a reasonable solution to this problem. Restraint is needed in this situation, and unfortunately, it appears that the only way to achieve that will be from federal scrutiny and possibly regulation.
BEFORE YOU GO…
… we’d like to ask for your support. More people are reading the Mississippi Business Journal than ever before, but advertising revenues for all conventional media are falling fast. Unlike many, we do not use a pay wall, because we want to continue providing Mississippi’s most comprehensive business news each and every day. But that takes time, money and hard work. We do it because it is important to us … and equally important to you, if you value the flow of trustworthy news and information which have always kept America strong and free for more than 200 years.
If those who read our content will help fund it, we can continue to bring you the very best in news and information. Please consider joining us as a valued member, or if you prefer, make a one-time contribution.Click for more info